Journal article
Crohn's disease management after intestinal resection: A randomised trial
P De Cruz, MA Kamm, AL Hamilton, KJ Ritchie, EO Krejany, A Gorelik, D Liew, L Prideaux, IC Lawrance, JM Andrews, PA Bampton, PR Gibson, M Sparrow, RW Leong, TH Florin, RB Gearry, G Radford-Smith, FA Macrae, H Debinski, W Selby Show all
Lancet | Published : 2015
Abstract
Background: Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery. This study aimed to identify the optimal strategy to prevent postoperative disease recurrence. Methods: In this randomised trial, consecutive patients from 17 centres in Australia and New Zealand undergoing intestinal resection of all macroscopic Crohn's disease, with an endoscopically accessible anastomosis, received 3 months of metronidazole therapy. Patients at high risk of recurrence also received a thiopurine, or adalimumab if they were intolerant to thiopurines. Patients were randomly assigned to parallel groups: colono..
View full abstractGrants
Funding Acknowledgements
AbbVie, Gutsy Group, Gandel Philanthropy, Angior Foundation, Crohn's Colitis Australia, and the National Health and Medical Research Council.